|
Variables
| |
Training (n = 183)
|
Validation (n = 79)
|
P
|
|---|
|
Age (years)
|
Median (q1–q3)
|
63.0 (56.0–70.0)
|
63.0 (59.0–67.5)
|
0.881
|
|
Gender
|
Male (%)
|
115 (62.8)
|
43 (54.4)
|
0.255
|
| |
Female (%)
|
68 (37.2)
|
36 (45.6)
| |
|
BMI (kg/m2)
|
Median (q1–q3)
|
22.4 (20.3–23.9)
|
21.8 (19.9–24.1)
|
0.353
|
|
CEA (ng/mL)
|
< 5 (%)
|
140 (76.5)
|
51 (64.6)
|
0.065
|
| |
≥ 5 (%)
|
43 (23.5)
|
28 (35.4)
| |
|
CA199 (U/mL)
|
< 37 (%)
|
49 (26.8)
|
16 (20.3)
|
0.334
|
| |
≥ 37 (%)
|
134 (73.2)
|
63 (79.7)
| |
|
CA125 (U/mL)
|
< 35 (%)
|
147 (80.3)
|
68 (86.1)
|
0.349
|
| |
≥ 35 (%)
|
36 (19.7)
|
11 (13.9)
| |
|
WBC (*10^9)
|
Median (q1–q3)
|
6.0 (4.8–7.3)
|
5.7 (4.4–6.8)
|
0.220
|
|
Hb (g/L)
|
Median (q1–q3)
|
127.0 (116.0–140.0)
|
129.0 (120.0–142.0)
|
0.110
|
|
Plt (*10^9)
|
Median (q1–q3)
|
191.0 (154.5–232.0)
|
204.0 (164.0–265.5)
|
0.132
|
|
Neut (*10^9)
|
Median (q1–q3)
|
3.9 (2.9–4.8)
|
3.4 (2.4–4.6)
|
0.093
|
|
Lymp (*10^9)
|
Median (q1–q3)
|
1.4 (1.1–1.7)
|
1.5 (1.1–1.9)
|
0.275
|
|
Mono (*10^9)
|
Median (q1–q3)
|
0.5 (0.4–0.6)
|
0.4 (0.3–0.6)
|
0.295
|
|
Alb (*10^9)
|
Median (q1–q3)
|
40.4 (37.3–43.3)
|
40.4 (36.4–43.4)
|
0.622
|
|
Glb (*10^9)
|
Median (q1–q3)
|
26.7 (24.3–29.5)
|
28.2 (26.1–31.9)
|
0.002
|
|
AGR
|
Median (q1–q3)
|
1.5 (1.4–1.7)
|
1.4 (1.2–1.6)
|
0.005
|
|
NLR
|
Median (q1–q3)
|
2.7 (2.0–4.2)
|
2.4 (1.6–3.3)
|
0.153
|
|
LMR
|
Median (q1–q3)
|
3.0 (2.1–4.2)
|
3.5 (2.0–5.1)
|
0.113
|
|
PLR
|
Median (q1–q3)
|
137.1 (106.3–184.1)
|
140.0 (96.6–217.2)
|
0.528
|
|
AST (U/L)
|
Median (q1–q3)
|
44.0 (20.5–111.5)
|
31 (20–90.5)
|
0.448
|
|
ALT (U/L)
|
Median (q1–q3)
|
50.0 (17.0–200.5)
|
29.0 (17.0–139.0)
|
0.119
|
|
ALP (U/L)
|
Median (q1–q3)
|
156.0 (89.5–391.5)
|
105.0 (67.5–367.0)
|
0.257
|
|
GGT (U/L)
|
Median (q1–q3)
|
159.0 (25.0–704.0)
|
51.0 (20.0–494.0)
|
0.162
|
|
TB (μmol/L)
|
Median (q1–q3)
|
22.1 (12.0–177.3)
|
14.6 (9.4–134.1)
|
0.716
|
|
DB (μmol/L)
|
Median (q1–q3)
|
6.4 (2.6–105.2)
|
5.5 (3.2–109.2)
|
0.360
|
|
Location
|
Head-isthmus (%)
|
139 (76.0)
|
54 (68.4)
|
0.259
|
| |
Body-tail (%)
|
44 (24.0)
|
25 (31.6)
| |
|
Margin
|
R0 (%)
|
176 (96.2)
|
79 (100.0)
|
0.106
|
| |
R1 (%)
|
7 (3.8)
|
0 (0.0)
| |
|
T stage
|
1 (%)
|
43 (23.5)
|
2 (2.5)
|
< 0.001
|
| |
2 (%)
|
86 (47.0)
|
55 (69.6)
| |
| |
3 (%)
|
54 (29.5)
|
22 (27.8)
| |
|
N stage
|
0 (%)
|
105 (57.4)
|
36 (45.6)
|
0.009
|
| |
1 (%)
|
56 (30.6)
|
39 (49.4)
| |
| |
2 (%)
|
22 (12.0)
|
4 (5.1)
| |
|
VI
|
Yes (%)
|
83 (45.4)
|
20 (25.3)
|
0.004
|
| |
No (%)
|
100 (54.6)
|
59 (74.7)
| |
|
PI
|
Yes (%)
|
143 (78.1)
|
67 (84.8)
|
0.283
|
| |
No (%)
|
40 (21.9)
|
12 (15.2)
| |
|
ATI
|
Yes (%)
|
82 (44.8)
|
43 (54.4)
|
0.195
|
| |
No (%)
|
101 (55.2)
|
36 (45.6)
| |
|
Differentiation
|
Well (%)
|
37 (20.2)
|
5 (6.3)
|
0.019
|
| |
Moderate (%)
|
133 (72.7)
|
68 (86.1)
| |
| |
Poor or undifferentiated (%)
|
13 (7.1)
|
6 (7.6)
| |
|
OS
|
Median (q1–q3)
|
19.0 (11.0–33.0)
|
14.0 (9.0–28.0)
|
0.340
|
|
RFS
|
Median (q1–q3)
|
11.0 (6.0–22.8)
|
8.0 (4.0–19.5)
|
0.503
|
|
1-year relapse
|
Yes (%)
|
106 (57.9)
|
49 (62.0)
|
0.629
|
| |
No (%)
|
77 (42.1)
|
30 (38.0)
| |
|
2-year relapse
|
Yes (%)
|
138 (75.4)
|
59 (74.7)
|
1.000
|
| |
No (%)
|
45 (24.6)
|
20 (25.3)
| |
- BMI body mass index, CEA carcinoembryonic antigen, CA cancer antigen, WBC white blood cell, Hb Hemoglobin, Plt Platelet, Neut neutrophil, Lymph lymphocyte, Mono monocyte, Alb albumin, Glb globulin, AGR albumin-globulin ratio, NLR neutrophil–lymphocyte ratio, LMR lymphcyte-monocyte ratio, PLR platelet-lymphocyte ratio, AST aspartate transaminase, ALT alanine transaminase, ALP alkaline phosphatase, GGT gamma-glutamyltransferase, TB total bilirubin, DB direct bilirubin, VI vascular invasion, PI perineural invasion, ATI adipose tissue invasion, OS overall survival, RFS relapse-free survival
